Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail ↗

January 27, 2025

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

Via Stocktwits

Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt ↗

January 17, 2025

Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.

Via Benzinga

Topics Government

Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In ↗

January 13, 2025

The two companies have collaborated since 2020 on the depression drug Zurzuvae, approved in 2023 by the FDA for treating postpartum depression.

Via Stocktwits

Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts ↗

January 13, 2025

Biogen proposes acquiring Sage Therapeutics for $7.22 per share, as analysts highlight the strategic value of Zurzuvae's success in postpartum depression.

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

January 02, 2025

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

December 16, 2024

Via Benzinga

Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics ↗

November 20, 2024

Via Benzinga

Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge ↗

January 13, 2025

Via Benzinga

Intra-Cellular Therapies, Standard BioTools, SI-BONE And Other Big Stocks Moving Higher On Monday ↗

January 13, 2025

Via Benzinga

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday? ↗

January 13, 2025

Sage Therapeutics reviews Biogen's $7.22 per share acquisition proposal amid ongoing restructuring and focus on Zurzuvae for postpartum depression.

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

January 13, 2025

Via Benzinga

Sage Therapeutics's Earnings: A Preview ↗

October 28, 2024

Via Benzinga

The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts ↗

October 04, 2024

Via Benzinga

Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts ↗

July 30, 2024

Via Benzinga

Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket ↗

January 13, 2025

Via Benzinga

This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

November 21, 2024

Via Benzinga

After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder ↗

November 20, 2024

Sage Therapeutics ends dalzanemdor development after Phase 2 trials for Huntington's and Alzheimer's fail to meet primary endpoints.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce ↗

October 17, 2024

Sage Therapeutics announces reorganization, including layoffs and pipeline changes, to support the launch of Zurzuvae. Focus shifts to Huntington's Disease trial after setbacks in essential tremor and...

Via Benzinga

Topics Workforce

Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday ↗

October 09, 2024

Via Benzinga

After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study ↗

October 08, 2024

Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

October 08, 2024

Via Benzinga

Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

October 04, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

October 04, 2024

Via Benzinga

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate ↗

September 26, 2024

Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a Phase 2 study, with Sage resuming full ownership of the asset by February...

Via Benzinga

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 24, 2024

Via Benzinga

Sage, Biogen Shelve Development Of Nervous System Disorder Drug After Data Disappoints ↗

July 24, 2024

Sage Therapeutics and Biogen will end further development of SAGE-324 in ET, focusing instead on evaluating future steps.

Via Benzinga

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 24, 2024

It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!

Via InvestorPlace

Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday ↗

July 19, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

Headline News about Sage Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today